Corrigendum to “Fibroblast growth factor 23 as a predictor of cardiovascular and all-cause mortality in prospective studies” [Atherosclerosis 261 (2017) 1–11, (S0021915017301442), (10.1016/j.atherosclerosis.2017.03.042)];Fibroblast growth factor 23 as a predictor of cardiovascular and all-cause mortality in prospective studies

Atherosclerosis

Volumn 261, Issue , 2017, Pages 1-11

  Qin, Zhexue ^a   Liu, Xi ^a   Song, Mingbao ^a   Zhou, Quan ^b   Yu, Jie ^a   Zhou, Baoshang ^a   Wu, Yazhou ^a   He, Yongming ^a   Huang, Lan ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b The First People s Hospital of Changde   (China)

Author keywords

Biomarker; Fibroblast growth factor 23; Mortality; Prognosis

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ALL CAUSE MORTALITY; ARTICLE; ASSOCIATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; DISEASE PREDISPOSITION; DOSE RESPONSE; FOLLOW UP; HUMAN; META ANALYSIS; MORTALITY; MORTALITY RISK; PRIORITY JOURNAL; PROSPECTIVE STUDY; ADULT; AGED; BLOOD; CAUSE OF DEATH; FEMALE; LEAST SQUARE ANALYSIS; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; RISK FACTOR; TIME FACTOR; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 85017302265     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2024.117583     Document Type: Erratum

References (68)

1. [1] Wolf, M., Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 82 (2012), 737–747.
2. [2] Sugimoto, H., Ogawa, T., Iwabuchi, Y., Otsuka, K., Nitta, K., Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients. Int. Urol. Nephrol. 46 (2014), 99–106.
3. [3] Chudek, J., Kocelak, P., Owczarek, A., Bozentowicz-Wikarek, M., Mossakowska, M., Olszanecka-Glinianowicz, M., Wiecek, A., Fibroblast growth factor 23 (FGF23) and early chronic kidney disease in the elderly. Nephrol. Dial. Transpl. 29 (2014), 1757–1763.
4. [4] Lee, J.E., Gohda, T., Walker, W.H., Skupien, J., Smiles, A.M., Holak, R.R., Jeong, J., McDonnell, K.P., Krolewski, A.S., Niewczas, M.A., Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1. PLoS One, 8, 2013.
5. [5] Seiler, S., Heine, G.H., Fliser, D., Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int. 76 (2009), S34–S42.
6. [6] Udell, J.A., O'Donnell, T., Morrow, D., Jarolim, P., Omland, T., Sloan, S., Pfeffer, M., Braunwald, E., Sabatine, M., Association of fibroblast growth factor (fgf)-23 levels with risk of cardiovascular events in patients with stable coronary artery disease. J. Am. Coll. Cardiol., 59, 2012 E1480.
7. [7] Ozkok, A., Kekik, C., Karahan, G.E., Sakaci, T., Ozel, A., Unsal, A., Yildiz, A., FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients. BMC Nephrol., 14, 2013.
8. [8] Jovanovich, A., Ix, J.H., Gottdiener, J., McFann, K., Katz, R., Kestenbaum, B., De Boer, I.H., Sarnak, M., Shlipak, M.G., Mukamal, K.J., Siscovick, D., Chonchol, M., Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis 231 (2013), 114–119.
9. [9] Polyakova, V., Poeling, J., Kubin, T., Braun, T., Walther, T., Richter, M.H., Fibroblast growth factor 23 is a promising biomarker of cardiac hypertrophy. J. Heart Lung Transpl., 33, 2014, S273.
10. [10] Nowak, A., Friedrich, B., Artunc, F., Serra, A., Breidthardt, T., Twerenbold, R., Peter, M., Potocki, M., Müller, C., Prognostic value and link to atrial fibrillation of circulating klotho and FGF23 in hemodialysis patients. Nephrol. Dial. Transpl., 28, 2013 i459.
11. [11] Alonso, A., Misialek, J.R., Eckfeldt, J.H., Selvin, E., Coresh, J., Chen, L.Y., Soliman, E.Z., Agarwal, S.K., Lutsey, P.L., Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: the atherosclerosis risk in communities study. J. Am. Heart Assoc., 3, 2014.
12. [12] Kurnatowska, I., Grzelak, P., Kaczmarska, M., Stefanczyk, L., Nowicki, M., Serum osteoprotegerin as a predictor of progression of atherosclerosis and coronary calcification in haemodialysis patients. NDT Plus, 3, 2010 iii187.
13. [13] Wright, C.B., Dong, C., Stark, M., Silverberg, S., Rundek, T., Elkind, M.S., Sacco, R.L., Mendez, A., Wolf, M., Plasma FGF23 and the risk of stroke: the Northern Manhattan study (NOMAS). Neurology 82 (2014), 1700–1706.
14. [14] Panwar, B., Jenny, N.S., Howard, V.J., Wadley, V.G., Muntner, P., Kissela, B.M., Judd, S.E., Gutiérrez, O.M., Fibroblast growth factor 23 and risk of incident stroke in community-living adults. Stroke 46 (2015), 322–328.
15. [15] Xiao, Y., Luo, X., Huang, W., Zhang, J., Peng, C., Fibroblast growth factor 23 and risk of all-cause mortality and cardiovascular events: a meta-analysis of prospective cohort studies. Int. J. Cardiol. 174 (2014), 824–828.
16. [16] Nowak, A., Artunc, F., Serra, A.L., Pollock, E., Krayenbühl, P.A., Müller, C., Friedrich, B., Sclerostin quo vadis? -Is this a useful long-term mortality parameter in prevalent hemodialysis patients?. Kidney Blood Press. Res. 40 (2015), 266–276.
17. [17] Brandenburg, V.M., Kleber, M.E., Vervloet, M.G., Tomaschitz, A., Pilz, S., Stojakovic, T., Delgado, G., Grammer, T.B., Marx, N., Marz, W., Scharnagl, H., Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen risk and cardiovascular health study. Atherosclerosis 237 (2014), 53–59.
18. [18] Fuernau, G., Pöss, J., Denks, D., Desch, S., Heine, G.H., Eitel, I., Seiler, S., de Waha, S., Ewen, S., Link, A., Schuler, G., Adams, V., Böhm, M., Thiele, H., Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Crit. Care, 18, 2014.
19. [19] Scialla, J.J., Parekh, R.S., Eustace, J.A., Astor, B.C., Plantinga, L., Jaar, B.G., Shafi, T., Coresh, J., Powe, N.R., Melamed, M.L., Race, mineral homeostasis and mortality in patients with end-stage renal disease on dialysis. Am. J. Nephrol. 42 (2015), 25–34.
20. [20] Chonchol, M., Greene, T., Zhang, Y., Hoofnagle, A.N., Cheung, A.K., Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. J. Am. Soc. Nephrol. 27 (2016), 227–237.
21. [21] Yang, H., Luo, H., Tang, X., Zeng, X., Yu, Y., Ma, L., Fu, P., Prognostic value of FGF23 among patients with end-stage renal disease: a systematic review and meta-analysis. Biomark. Med. 10 (2016), 547–556.
22. [22] Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D., Moher, D., Becker, B.J., Sipe, T.A., Thacker, S.B., Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283 (2000), 2008–2012.
23. [23] Stang, A., Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25 (2010), 603–605.
24. [24] Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat. Med. 21 (2002), 1539–1558.
25. [25] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
26. [26] DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin. Trials 7 (1986), 177–188.
27. [27] Higgins, J.P.T., Green, S., Cochrane handbook for Systematic Reviews of Interventions. 2011, Wiley-Blackwell, Chichester, England; Hoboken, NJ.
28. [28] Begg, C.B., Mazumdar, M., Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994), 1088–1101.
29. [29] Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
30. [30] Duval, S., Tweedie, R., Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56 (2000), 455–463.
31. [31] Greenland, S., Longnecker, M.P., Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am. J. Epidemiol. 135 (1992), 1301–1309.
32. [32] Orsini, N., Bellocco, R., Greenland, S., Generalized least squares for trend estimation of summarized dose-respose data. Stata J. 6 (2006), 40–57.
33. [33] Shao, C., Tang, H., Zhao, W., He, J., Nut intake and stroke risk: a dose-response meta-analysis of prospective cohort studies. Sci. Rep., 6, 2016, 30394.
34. [34] Jean, G., Terrat, J.C., Vanel, T., Hurot, J.M., Lorriaux, C., Mayor, B., Chazot, C., High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol. Dial. Transpl. 24 (2009), 2792–2796.
35. [35] Olauson, H., Qureshi, A.R., Miyamoto, T., Barany, P., Heimburger, O., Lindholm, B., Stenvinkel, P., Larsson, T.E., Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship?. Nephrol. Dial. Transpl. 25 (2010), 3033–3038.
36. [36] Parker, B.D., Schurgers, L.J., Brandenburg, V.M., Christenson, R.H., Vermeer, C., Ketteler, M., Shlipak, M.G., Whooley, M.A., Ix, J.H., The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the heart and soul study. Ann. Intern. Med. 152 (2010), 640–648.
37. [37] Isakova, T., Xie, H., Yang, W., Xie, D., Anderson, A.H., Scialla, J., Wahl, P., Gutiérrez, O.M., Steigerwalt, S., He, J., Schwartz, S., Lo, J., Ojo, A., Sondheimer, J., Hsu, C.Y., Lash, J., Leonard, M., Kusek, J.W., Feldman, H.I., Wolf, M., Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305 (2011), 2432–2439.
38. [38] Wolf, M., Molnar, M.Z., Amaral, A.P., Czira, M.E., Rudas, A., Ujszaszi, A., Kiss, I., Rosivall, L., Kosa, J., Lakatos, P., Kovesdy, C.P., Mucsi, I., Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J. Am. Soc. Nephrol. 22 (2011), 956–966.
39. [39] Ix, J.H., Katz, R., Kestenbaum, B.R., De Boer, I.H., Chonchol, M., Mukamal, K.J., Rifkin, D., Siscovick, D.S., Sarnak, M.J., Shlipak, M.G., Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J. Am. Coll. Cardiol. 60 (2012), 200–207.
40. [40] Nakano, C., Hamano, T., Fujii, N., Obi, Y., Matsui, I., Tomida, K., Mikami, S., Inoue, K., Shimomura, A., Nagasawa, Y., Okada, N., Tsubakihara, Y., Rakugi, H., Isaka, Y., Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone 50 (2012), 1266–1274.
41. [41] Arnlov, J., Carlsson, A.C., Sundstrom, J., Ingelsson, E., Larsson, A., Lind, L., Larsson, T.E., Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int. 83 (2013), 160–166.
42. [42] Baia, L.C., Humalda, J.K., Vervloet, M.G., Navis, G., Bakker, S.J., de Borst, M.H., Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin. J. Am. Soc. Nephrol. 8 (2013), 1968–1978.
43. [43] Westerberg, P.A., Tivesten, A., Karlsson, M.K., Mellstrom, D., Orwoll, E., Ohlsson, C., Larsson, T.E., Linde, T., Ljunggren, O., Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs). BMC Nephrol., 14, 2013, 85.
44. [44] Lutsey, P.L., Alonso, A., Selvin, E., Pankow, J.S., Michos, E.D., Agarwal, S.K., Loehr, L.R., Eckfeldt, J.H., Coresh, J., Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the atherosclerosis risk in communities study. J. Am. Heart Assoc., 3, 2014.
45. [45] Nowak, A., Friedrich, B., Artunc, F., Serra, A.L., Breidthardt, T., Twerenbold, R., Peter, M., Mueller, C., Prognostic value and link to atrial fibrillation of soluble klotho and FGF23 in hemodialysis patients. PLoS ONE, 9, 2014.
46. [46] Udell, J.A., Morrow, D.A., Jarolim, P., Sloan, S., Hoffman, E.B., O'Donnell, T.F., Vora, A.N., Omland, T., Solomon, S.D., Pfeffer, M.A., Braunwald, E., Sabatine, M.S., Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J. Am. Coll. Cardiol. 63 (2014), 2421–2428.
47. [47] Haring, R., Enserro, D., Xanthakis, V., Mitchell, G.F., Benjamin, E.J., Hamburg, N.M., Sullivan, L., Nauck, M., Wallaschofski, H., Vasan, R.S., Plasma fibroblast growth factor 23: clinical correlates and association with cardiovascular disease and mortality in the framingham heart study. J. Am. Heart Assoc., 5, 2016.
48. [48] Souma, N., Isakova, T., Lipiszko, D., Sacco, R.L., Elkind, M.S., DeRosa, J.T., Silverberg, S.J., Mendez, A.J., Dong, C., Wright, C.B., Wolf, M., Fibroblast growth factor 23 and cause-specific mortality in the general population: the Northern Manhattan study. J. Clin. Endocrinol. Metab. 101 (2016), 3779–3786.
49. [49] Smith, E.R., McMahon, L.P., Holt, S.G., Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs. Clin. Chem. Lab. Med. 51 (2013), 1971–1981.
50. [50] Gutiérrez, O.M., Mannstadt, M., Isakova, T., Rauh-Hain, J.A., Tamez, H., Shah, A., Smith, K., Lee, H., Thadhani, R., Jüppner, H., Wolf, M., Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359 (2008), 584–592.
51. [51] Dalal, M., Sun, K., Cappola, A.R., Ferrucci, L., Crasto, C., Fried, L.P., Semba, R.D., Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women. Eur. J. Endocrinol. 165 (2011), 797–803.
52. [52] Mirza, M.A.I., Alsiö, J., Hammarstedt, A., Erben, R.G., Michaëlsson, K., Tivesten, Å., Marsell, R., Orwoll, E., Karlsson, M.K., Ljunggren, Ö., Mellström, D., Lind, L., Ohlsson, C., Larsson, T.E., Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 219–227.
53. [53] Kendrick, J., Cheung, A.K., Kaufman, J.S., Greene, T., Roberts, W.L., Smits, G., Chonchol, M., Jamison, R.L., Hartigan, P., Kaufman, J., Goldfarb, D.S., Warren, S.R., Guarino, P.D., Gaziano, J.M., FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J. Am. Soc. Nephrol. 22 (2011), 1913–1922.
54. [54] Dominguez, J.R., Shlipak, M.G., Whooley, M.A., Ix, J.H., Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes. J. Am. Soc. Nephrol. 24 (2013), 647–654.
55. [55] Erben, R.G., Update on FGF23 and klotho signaling. Mol. Cell Endocrinol. 432 (2016), 56–65.
56. [56] Leifheit-Nestler, M., Grosse Siemer, R., Flasbart, K., Richter, B., Kirchhoff, F., Ziegler, W.H., Klintschar, M., Becker, J.U., Erbersdobler, A., Aufricht, C., Seeman, T., Fischer, D.C., Faul, C., Haffner, D., Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol. Dial. Transpl. 31 (2015), 1088–1099.
57. [57] Andrukhova, O., Slavic, S., Odorfer, K.I., Erben, R.G., Experimental myocardial infarction upregulates circulating fibroblast growth Factor-23. J. Bone Min. Res. 30 (2015), 1831–1839.
58. [58] Hori, M., Nishida, K., Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc. Res. 81 (2009), 457–464.
59. [59] Shalhoub, V., Shatzen, E.M., Ward, S.C., Davis, J., Stevens, J., Bi, V., Renshaw, L., Hawkins, N., Wang, W., Chen, C., Tsai, M.M., Cattley, R.C., Wronski, T.J., Xia, X., Li, X., Henley, C., Eschenberg, M., Richards, W.G., FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J. Clin. Invest 122 (2012), 2543–2553.
60. [60] Faul, C., Amaral, A.P., Oskouei, B., Hu, M.C., Sloan, A., Isakova, T., Gutierrez, O.M., Aguillon-Prada, R., Lincoln, J., Hare, J.M., Mundel, P., Morales, A., Scialla, J., Fischer, M., Soliman, E.Z., Chen, J., Go, A.S., Rosas, S.E., Nessel, L., Townsend, R.R., Feldman, H.I., St John Sutton, M., Ojo, A., Gadegbeku, C., Di Marco, G.S., Reuter, S., Kentrup, D., Tiemann, K., Brand, M., Hill, J.A., Moe, O.W., Kuro, O.M., Kusek, J.W., Keane, M.G., Wolf, M., FGF23 induces left ventricular hypertrophy. J. Clin. Invest 121 (2011), 4393–4408.
61. [61] Grabner, A., Amaral, A.P., Schramm, K., Singh, S., Sloan, A., Yanucil, C., Li, J., Shehadeh, L.A., Hare, J.M., David, V., Martin, A., Fornoni, A., Di Marco, G.S., Kentrup, D., Reuter, S., Mayer, A.B., Pavenstadt, H., Stypmann, J., Kuhn, C., Hille, S., Frey, N., Leifheit-Nestler, M., Richter, B., Haffner, D., Abraham, R., Bange, J., Sperl, B., Ullrich, A., Brand, M., Wolf, M., Faul, C., Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 22 (2015), 1020–1032.
62. [62] Jimbo, R., Kawakami-Mori, F., Mu, S., Hirohama, D., Majtan, B., Shimizu, Y., Yatomi, Y., Fukumoto, S., Fujita, T., Shimosawa, T., Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int. 85 (2014), 1103–1111.
63. [63] Jimbo, R., Shimosawa, T., Cardiovascular risk factors and chronic kidney disease-FGF23: a key Molecule in the cardiovascular disease. Int. J. Hypertens., 2014, 2014, 381082.
64. [64] Silswal, N., Touchberry, C.D., Daniel, D.R., McCarthy, D.L., Zhang, S., Andresen, J., Stubbs, J.R., Wacker, M.J., FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am. J. Physiol. Endocrinol. Metab. 307 (2014), E426–E436.
65. [65] Lindberg, K., Olauson, H., Amin, R., Ponnusamy, A., Goetz, R., Taylor, R.F., Mohammadi, M., Canfield, A., Kublickiene, K., Larsson, T.E., Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS one, 8, 2013 e60658.
66. [66] Scialla, J.J., Lau, W.L., Reilly, M.P., Isakova, T., Yang, H.Y., Crouthamel, M.H., Chavkin, N.W., Rahman, M., Wahl, P., Amaral, A.P., Hamano, T., Master, S.R., Nessel, L., Chai, B., Xie, D., Kallem, R.R., Chen, J., Lash, J.P., Kusek, J.W., Budoff, M.J., Giachelli, C.M., Wolf, M., Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int. 83 (2013), 1159–1168.
67. [67] Esposito, K., Chiodini, P., Capuano, A., Bellastella, G., Maiorino, M.I., Giugliano, D., Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine 45 (2014), 28–36.
68. [68] Sun, N., Guo, Y., Liu, W., Densmore, M., Shalhoub, V., Erben, R.G., Ye, L., Lanske, B., Yuan, Q., FGF23 neutralization improves bone quality and osseointegration of titanium implants in chronic kidney disease mice. Sci. Rep., 5, 2015, 8304.